Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373516 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis
A Phase 2 study, sponsored by QuatRx Pharmaceuticals Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00373516 is a Phase 2 study that has completed, run by QuatRx Pharmaceuticals Company. The registered enrollment target is 150 participants.
The verdict
NCT00373516, a Phase 2 study, has completed, sponsored by QuatRx Pharmaceuticals Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of QRX-101 ointment (75 mcg/g QD and 75mcg/g BID) in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks
Interventions
- DRUG Vehicle (Placebo) applied BID
- DRUG QRX-101 75 mcg/g ointment applied QD
- DRUG QRX-101 75 mcg/g ointment applied BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373516
The ClinicalTrials.gov registry entry for NCT00373516 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QuatRx Pharmaceuticals Company, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle (Placebo) applied BID is the first listed.
NCT00373516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00373516 about?
NCT00373516 is a clinical study titled "Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis". The purpose of this study is to evaluate the efficacy and safety of two dosing regimens of QRX-101 ointment (75 mcg/g QD and 75mcg/g BID) in the treatment of plaque-type psoriasis when applied topically twice daily for 8 weeks
What is the current status of trial NCT00373516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-09. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00373516?
The interventions under investigation include: Vehicle (Placebo) applied BID (DRUG), QRX-101 75 mcg/g ointment applied QD (DRUG), QRX-101 75 mcg/g ointment applied BID (DRUG).
Who is sponsoring clinical trial NCT00373516?
This trial is sponsored by QuatRx Pharmaceuticals Company, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.